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A B S T R A C T
Nitric oxide (NO) production plays a central role in conferring tolerance to hypoxia. Tibetan highlanders, suc-
cessful high-altitude dwellers for millennia, have higher circulating nitrate and exhaled NO (ENO) levels than
native lowlanders. Since nitrate itself can reduce the oxygen cost of exercise in normoxia it may confer additional
beneﬁts at high altitude. Xtreme Alps was a double-blinded randomised placebo-controlled trial to investigate
how dietary nitrate supplementation aﬀects physiological responses to hypoxia in 28 healthy adult volunteers
resident at 4559m for 1 week; 14 receiving a beetroot-based high-nitrate supplement and 14 receiving a low-
nitrate ‘placebo’ of matching appearance/taste. ENO, vital signs and acute mountain sickness (AMS) severity were
recorded at sea level (SL) and daily at altitude. Moreover, standard spirometric values were recorded, and saliva
and exhaled breath condensate (EBC) collected. There was no signiﬁcant diﬀerence in resting cardiorespiratory
variables, peripheral oxygen saturation or AMS score with nitrate supplementation at SL or altitude. Median ENO
levels increased from 1.5/3.0 mPa at SL, to 3.5/7.4 mPa after 5 days at altitude (D5) in the low and high-nitrate
groups, respectively (p= 0.02). EBC nitrite also rose signiﬁcantly with dietary nitrate (p=0.004),
1.7–5.1 μMat SL and 1.6–6.3 μMat D5, and this rise appeared to be associated with increased levels of ENO.
However, no signiﬁcant changes occurred to levels of EBC nitrate or nitrosation products (RXNO). Median
salivary nitrite/nitrate concentrations increased from 56.5/786 μM to 333/5,194 μM with nitrate supple-
mentation at SL, and changed to 85.6/641 μM and 341/4,553 μM on D5. Salivary RXNO rose markedly with
treatment at SL from 0.55 μM to 5.70 μM. At D5 placebo salivary RXNO had increased to 1.90 μM whilst
treatment RXNO decreased to 3.26 μM. There was no association with changes in any observation variables or
AMS score. In conclusion, dietary nitrate supplementation is well tolerated at altitude and signiﬁcantly increases
pulmonary NO availability and both salivary and EBC NO metabolite concentrations. Surprisingly, this is not
associated with changes in hemodynamics, oxygen saturation or AMS development.
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1. Introduction
The partial pressure of oxygen decreases on ascent to high altitude
as a result of a decline in barometric pressure; at 5300m (the height of
Everest base camp) it is approximately half the value at sea level [1].
This hypobaric hypoxia causes hypoxaemia (a lack of oxygen in the
blood) resulting in signiﬁcant physiological challenges. The respiratory
system is particularly aﬀected, and consequently respiratory problems
make up some of the most common (e.g. high altitude cough) and also
the most serious (e.g. high altitude pulmonary oedema or HAPE) ill-
nesses encountered at high altitude [2]. Respiratory pathologies and
hypoxaemia are also commonly encountered in critical care patients
but are very diﬃcult to study in this setting. High altitude environments
might therefore provide a model for pathological hypoxaemia from
which much can be learned [3].
Interestingly, native lowlanders appear to respond to acute hypo-
baric hypoxia diﬀerently from native highlanders (i.e. populations
permanently residing above 3000m). For example, native lowlanders
seem to rely heavily on increased erythropoiesis to maintain oxygen
content at altitude [1], whilst this response is much less pronounced in
native highlanders such as the Sherpas (supremely adapted after living
at high altitude for over 500 generations) [4]. Another notable diﬀer-
ence that is remarkably conserved across diﬀerent high altitude popu-
lations (including the Tibetan populations and the Bolivian Aymara) is
that mountain dwellers exhale higher concentrations of nitric oxide
(NO) compared to individuals living at sea level [5,6]. However, ex-
haled NO levels decrease signiﬁcantly in lowland populations on acute
exposure to altitude [7]. During graded exposure to altitude, however,
NO production increases also in lowlanders suggesting that NO pro-
duction and particularly respiratory NO availability might play an im-
portant role in oﬀsetting the eﬀect of hypoxia and improve performance
[8].
NO is a ubiquitous signalling and eﬀector molecule, and an im-
portant modulator of oxygen delivery through eﬀects on blood pressure
and blood ﬂow as well as mitochondrial respiration. As well as these
vasoactive properties, it also plays crucial roles in inﬂammation (in-
cluding pulmonary and airway inﬂammation) and in the immune
system, as a cytotoxic entity and by abating oxidative stress [9].
Moreover, in hypoxia it plays a key role in energy supply-demand
matching [10]. Inhaled NO has been shown to reduce pulmonary artery
pressures and increase arterial oxygenation in critical care patients
suﬀering from Acute Respiratory Distress Syndrome by improving
ventilation-perfusion matching [11]. Inhaled NO has also been used to
treat patients suﬀering from HAPE, successfully reducing oedema and
increasing arterial oxygenation [12].
NO is produced through two main pathways in the body, both
regulated by oxygen. While the enzymatic formation of NO from L-ar-
ginine by nitric oxide synthases (NOS) is an oxygen-requiring process,
production of NO through serial reduction of inorganic nitrate (NO3−)
to nitrite (NO2−) and NO is inhibited by oxygen [13]. It is this second
mechanism that is thought to underlie the signiﬁcant increase in mar-
kers of NO metabolism observed in acclimatizing lowlanders and also
well-adapted Sherpas at high altitude [8]. Dietary nitrate is initially
reduced to nitrite by the oral bacterial ﬂora in the mouth, before nitrite
can be further reduced to NO in the acidic environment of the stomach
and in vascular tissue by various nitrite reductase enzymes [14–16].
Besides its use as an ergogenic aid in sports medicine [17–21], at-
tempts to increase nitrate intake through dietary supplements have also
been trialled as therapeutic interventions in respiratory patients suf-
fering from chronic obstructive pulmonary disease (COPD), which re-
sults in a chronic hypoxaemic state, with mixed results [22–26]. Some
studies showed beneﬁcial eﬀects such as increased exercise perfor-
mance and lower resting blood pressure [22,24], whilst other studies
did not show any signiﬁcant improvements in exercise performance
[25,26]. Some studies only showed limited improvements (such as re-
duced oxygen consumption) but suggested that these beneﬁts might be
greatest in the most hypoxic patients [23]. However, all of these studies
demonstrated that dietary nitrate supplementation is both safe and
tolerable to patients. If dietary nitrate supplementation could improve
physiological performance under other hypoxic conditions then it could
potentially be an eﬀective and economic treatment for hypoxaemia in
critically ill patients.
The Xtreme Alps expedition was a double-blinded randomised pla-
cebo-controlled trial designed to investigate how dietary nitrate sup-
plementation aﬀects performance at altitude [27]. This report focuses
on the ﬁndings of the study's respiratory outcomes, baseline observa-
tions and acute mountain sickness (AMS) scores.
2. Methods
2.1. Study setting and participants
Details of the Xtreme Alps expedition and protocols have been
previously described [27]. A total of 28 healthy adult volunteers (aged
21–40 years) were recruited after completing a health screening process
to identify those at risk of problems at high altitude (as detailed in
[27]). Of these, 21 (75%) were male. The mean weight was 73.3 kg
(± 11.6), mean height 1.76m (±0.08), and mean BMI 23.6 (± 2.7).
3.6% were smokers and 75% had previously been to an altitude of over
3000m. Anyone deemed unﬁt to undergo a formal exercise test at high
altitude (as previously described [28]) was excluded. Written informed
consent was obtained from each participant and ethical approval for the
study was obtained from Research Ethics Committees at both University
College London, UK and the University of Turin, Italy.
The study took place in August 2010 at the Capanna Regina
Margherita (‘Margherita Hut’) on the summit of Monte Rosa (altitude
4559m), which contains a research laboratory inside, managed by the
University of Turin. Baseline measurements were conducted in London
(altitude 75m) six weeks earlier: mean barometric pressure 100.5 kPa,
mean laboratory temperature 24.1 °C and mean oxygen partial pressure
19.7 kPa. Participants were then separated into 2 groups (Trek 1 and 2)
based on their availability, with Trek 2 starting their ascent seven days
after Trek 1. All investigators and participants initially ﬂew to Milan
(102m) and remained there one night before starting to ascend the
following day; by road to Alagna (1205m), by lift to Punta Indren
(3250m), and then on foot to the Gnifetti Hut (3611m). Severe weather
conditions meant Trek 1 only stayed at 3611m for two nights before
ascending on foot to the Margherita Hut, whilst Trek 2 ascended on foot
after three nights at 3611m. Subjects then remained at 4559m for the
rest of the study duration (eight nights for Trek 1, seven for Trek 2) (see
Fig. 1A) before descending on foot again. This schedule included a
planned rest day on arrival at 4559m for each group (during which the
ﬁrst group could build and set up the laboratory), followed by 5 days of
testing. In the laboratory at 4559m, the mean barometric pressure,
temperature and partial pressure of oxygen were 78.1 kPa, 22.6 °C and
15.1 kPa respectively.
2.2. Randomisation
Following enrolment, participants were randomly allocated to re-
ceive either a high nitrate supplement (intervention group) or low ni-
trate supplement (placebo group) in accordance with the CONSORT
2010 guidelines (http://www.consort-statement. org/) and accounting
for the need for equal numbers of individuals in both groups whilst
maintaining gender distribution. Both participants and investigators
were blinded to group allocations for the duration of the study, in-
cluding the analysis of the primary data sets.
2.3. Intervention
The intervention juice was a custom formulated all-natural beet-
root/fruit juice blend (produced, pasteurised and packaged into 200mL
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food-grade aluminum foil pouches individually labelled with anon-
ymized subject codes by Aurapa GmbH, Bietigheim-Bissingen,
Germany). The total daily nitrate dose targeted by the high nitrate in-
tervention was similar to that shown by others to be eﬀective in im-
proving exercise performance at sea level (range 0.10–0.18mmol/kg/
day) [29,30], and divided into three individual doses for consumption
in the morning, at midday and in the evening. The low-nitrate (placebo)
version was produced in the same manner using beetroot juice in which
the majority of nitrate had been removed by selective microbial deni-
triﬁcation. Administration, both at sea level and high altitude, com-
menced 72 h prior to the start of and continued throughout each testing
period. However, as all subjects in both the placebo and treatment
groups were taking beetroot juice for 3 days prior to each experimental
period starting, we were unable to measure baseline (or 'treatment-free'
control) measurements either at sea level or at altitude in either of these
groups. A limited amount of data is available for ENO and breath con-
densate levels from treatment-naïve members of the laboratory team,
who did not receive any supplement as they were not part of the main
study; this data is presented where available on the appropriate ﬁgures.
However, the error bars for this group are large as the n-values are
small and often variable (not all individuals were always available and
some unwell, requiring medication and/or experiencing respiratory
inﬂammation on certain days) – these individuals were never intended
to be part of the main study but presented here for comparison to the
placebo group. All meals consumed by subjects during the study period
were standardised in order to minimise nutritional nitrate intake.
2.4. Daily diary, measuring observations & AMS scores
All participants completed a daily diary ﬁrst thing each morning
before any oral intake (including food, caﬀeine, placebo or intervention
supplements). Peripheral oxygen saturation (SpO2), heart rate (HR),
respiratory rate (RR) and blood pressure (BP) were measured after ﬁve
minutes of rest, sitting upright. Finally, each participant also recorded
medications taken and their symptoms according to the Lake Louise
score – a validated score for diagnosing and grading AMS [31,32].
2.5. Respiratory measurements
Standard spirometric variables (FEV1, FVC, FEV1/FVC, PEF and FEF
25–75) were measured using an ultrasonic spirometer (Easy-One, NDD
Medical Technologies, MA, USA). Due to a corrupted ﬁle all spirometric
recordings taken at high altitude were lost; therefore, only sea level
data are reported.
Breath-to-breath analysis of inhaled and exhaled NO was performed
using a spirometric analysis device (using individual disposable
Spirettes and bacterial ﬁlters) connected to a gas phase chemilumi-
nescence analyzer (CLD88sp with Spiroware software, EcoMedics,
Duernten, Switzerland); two identical units were used in parallel
throughout. In accordance with current American Thoracic Society/
European Respiratory Society recommendations for exhaled NO mea-
surements [33], individual Denox 88 units (EcoMedics, Duernten,
Switzerland) provided NO-free air and enabled advanced adaptive ex-
piratory ﬂow control. Expiratory gas ﬂow was measured in real time
according to the time-of-ﬂight principle using a high resolution/high
frequency ultrasonic device. A fraction of inspired and expired air
(∼10% of the expired air at a nominal ﬂow of 50ml/s) was continually
transferred from a sidestream opening in the handheld spirometer;
here, ﬂow was controlled using a ﬁxed oriﬁce in the sample line with a
vacuum pump driven internal resistor arrangement, maintaining a
constant ﬂow of 300ml/min of sampled air into the analyzer, in-
dependent of changes in barometric pressure.
Both chemiluminescence analysers were equipped with additional
stainless-steel bulkhead ﬁttings, which supplied their ozone generators
with pure oxygen (instead of environmental air) from a cylinder. This
hardware adjustment ensured adequate ozone generation to maintain
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Fig. 1. Changes in resting physiological variables during the Xtreme Alps expedition. All
values are presented as means ± SEM, displayed separately for Trek 1 and Trek 2 (solid
and dotted lines, respectively) as Trek 1 ascended one day faster from the Gnifetti Hut
(3611m) to the Margherita Hut (4559m) due to inclement weather conditions. Each
arrow represents the administration of 3 x doses of either treatment or placebo supple-
ment (1 dose before every meal each day), starting 3 days prior to each testing period.
SL= sea level testing, D1 – D5= altitude testing days 1–5. Panel 1A - ascent proﬁle, 1B -
resting oxygen saturation per expedition day, 1C – resting respiration rate, 1D – resting
heart rate, and 1E – resting blood pressure (systolic over diastolic).
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optimal performance even at lower barometric pressures. For con-
sistency, medical grade oxygen was also used to supply the ozone
generators at sea level. All measurement devices were calibrated daily,
both at sea level and at altitude, with NO (4.00 ppm) using 100% ni-
trogen as zero gas and a calibrated 100 mL volumetric syringe. The
CLD88sp devices measure continuously ambient temperature and
pressure by internal sensors. Each morning accurate barometric pres-
sure and temperature were entered into the software for veriﬁcation
purposes as part of the calibration procedure. The CLD88sp takes the
ambient pressure into account during the gas calibration and compen-
sates automatically for diurnal pressure changes. Thus, displayed FeNO
concentrations are always accurate and do not require correction for
altitude. However, criticism has been raised in relation to other devices
and measurement principles using e.g. electrochemical cells for NO
detection where readings can vary with changes in partial pressure
[34,35]. Moreover, the partial pressure of metabolically active gases
within a body cavity may more accurately represent biological activity
[34]. Therefore we here report both fractional exhaled NO (FeNO) and
partial pressures of exhaled NO (PeNO).
For each measurement subjects inspired to total lung capacity be-
fore slowly expiring against a deﬁned resistance to ensure proper velum
closure. During expiration an electronic visual display helped each
subject maintain a steady ﬂow of 50ml/s in accordance with ATS
guidelines - a smiley face against a green background was displayed
when the ultrasonically measured ﬂow was within limits (50ml/
s± 5%), with red warning signs ﬂashing when the ﬂow fell below the
minimum or exceeded the maximum level. A minimum of 3 successful
repeats with stable ﬂow rates for at least 6 s were collected for each
measurement.
2.6. Measures of nitric oxide/nitrate metabolites
Samples of unstimulated saliva were collected using dedicated col-
lection devices (Salimetrics Oral Swabs; State College, PA, USA) im-
mediately before participants ate their midday meal. Swabs were
placed sublingually for 2min at sea level or 5min at altitude (to enable
suﬃcient volume to be collected for analysis) before collection into a
sterile container and centrifugation at 3000 rpm for 15min; 1ml of
saliva was aliquoted and stored in two separate cryovials at−40 °C for
later determination of nitrosation products, nitrite and nitrate. Subjects
had not consumed their respective supplement, brushed their teeth, or
had recent acute hypoxic or hyperoxic exposure (e.g. as part of other
research protocols) before sample collection.
Exhaled breath condensate (EBC), a readout of alveolar surface
chemistry, was collected non-invasively by breathing through a
mouthpiece connected to a sampling tube (pre-rinsed with ultrapure
Millipore water (EMD MilliporeSigma, MA, USA) and dried before use)
contained within an insulated pre-cooled aluminium sleeve (RTube®,
Respiratory Research, Inc., Charlottesville, VA, USA) for 15min. Two
1ml EBC aliquots were frozen and stored at −40 °C straight after col-
lection and analysed later in the UK.
Placebo and intervention juices were saved along with re-
presentative food samples served at Margherita Hut. Food samples were
collected, homogenized in phosphate buﬀer (or drinking water), frozen
at −40 °C straight after homogenisation and analysed later in the UK.
NO metabolite concentrations were quantiﬁed using reductive gas-
phase chemiluminescence (for determination of total nitrosation pro-
ducts, RXNO) and HPLC (for nitrite and nitrate), as described elsewhere
[8].
2.7. Analysis plan
Sea level spirometry values were normally distributed when tested.
Separate t-tests, performed in GraphPad Prism 6 software (www.
graphpad.com/scientiﬁc-software/prism), were used to analyse these
variables (FEV1, FVC, FEV1/FVC, PEF & FEF 25–75) as there was no
requirement to model for diﬀerent ascent proﬁles.
Statistical analyses for ENO, breath condensate and saliva measure-
ments were all performed using linear mixed modeling in STATA 11
(http://www.stata.com) to account for the multiple time points at
which measurements were taken as well as the nitrate intervention. All
physiological observations were normally distributed, as were all other
measured variables after logarithmic transformation. All statistical tests
(except those spirometry values listed above) were performed on
parametric log-transformed data. Signiﬁcance was assumed when
p < 0.05. A sensitivity analysis was performed with missing values
replaced by mean values to verify the model. Correlation between
breath condensate nitrite and ENO was performed on non-parametric
untransformed data using Spearman's Rank with a 2-tailed signiﬁcance
test. Physiological observations and AMS scores are reported as means
(± standard deviation). For easier reading, all other values are re-
ported in the text as median (interquartile range) of anti-logged/un-
transformed data (non-parametric) to allow presentation in original
units.
3. Results
3.1. Dietary nitrate intake and supplementation
The nitrate concentration of the placebo supplement was 1.4
(± 0.1) mM; consumption of 3× 200mL therefore amounted to
11.5 μmoles/kg bw per day (bw=body weight), which is less than the
average UK daily intake of around 24.5 μmoles/kg bw per person per
day [36]. The intervention supplement had a nitrate concentration of
18.5 (± 2.0) mM, translating into> 10 times higher dietary nitrate
supplementation levels in the intervention group. Nitrite concentration
was below 1 μM in placebo and 2.4 μM in the intervention group, which
amount to< 0.01 and 0.02 μmole/kg bw per day, respectively – both
well below the average UK daily intake of 0.53 μmole/kg bw per day.
Where available, the limited measurements we have of untreated adults
at altitude closely matched the respective values for the placebo group.
Food provided at altitude varied somewhat from day to day,
therefore representative food samples were collected from typical meals
(breakfast, lunch, dinner). Average ranges per meal for nitrate were as
follows: 50–217 μmoles for breakfast, 132–447 μmoles for lunch, and
559–1201 μmoles for dinner. The average ranges per meal for nitrite
were considerably smaller, amounting to 0.17–0.46 μmoles for break-
fast, 0.64–1.40 μmoles for lunch, and 0.71–2.10 μmoles for dinner. This
amounted to an average intake of 18 (± 11) μmoles nitrate/kg bw per
day and 0.038 (± 0.023) μmoles nitrite/kg bw per day, well within
normal UK daily intakes [36]. Combined, the placebo group received an
average of 29.5 μmoles nitrate/kg bw per day, slightly (20%) above the
average UK intake whilst the intervention group received up to
186 μmol nitrate/kg bw per day, or 6.6 times larger than the normal UK
daily intake with minimal addition of nitrite from either placebo or
intervention to the diet.
3.2. Baseline physiological observations
Increasing exposure to hypobaric hypoxia at high altitude produced
marked changes in participants' resting physiological variables (see
Fig. 1). Resting SpO2 initially decreased with each incremental rise in
altitude, before stabilising as further time was spent at each elevation
(see Fig. 1B). Meanwhile, resting respiration rates (RR) initially in-
creased on ascent before trending back towards baseline values (see
Fig. 1C). Mean resting SpO2 at sea level was 98.3% (± 1.1) and 97.7%
(±1.5) for Trek 1 and 2 respectively, decreasing to 77.3% (± 8.0) and
81.1% (± 6.84) on their ﬁrst day at 4,559m (day 3 and day 4, re-
spectively). Mean RRs for Trek 1 and 2 respectively were 10.6 (± 2.9)
and 11.8 (± 2.6) at sea level, increasing to 16.1 (± 5.7) and 14.2
(± 4.0) at arriving at 4,559m, and decreasing to 12.3 (± 3.1) and
11.9 (± 3.1) by day 10. A similar response pattern was also seen for
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resting heart rate and blood pressure (Fig. 1D and E). All physiological
trends were similar between both ascent proﬁles; hence all other
measurements were pooled for subsequent analysis.
3.3. Acute mountain sickness (AMS)
There was no signiﬁcant diﬀerence in the incidence of Acute
Mountain Sickness (AMS) between the intervention and placebo
groups, p= 0.29 (see Fig. 2). Similarly, the dietary nitrate supplement
did not signiﬁcantly alter the incidence of headache at altitude
(p=0.47). Both of these ﬁndings remained consistent when the dif-
ferent ascent rate (diﬀerent trek groups) was also included in the linear-
regression model. One subject was evacuated hours after arriving at
4559m after developing high altitude cerebral oedema (HACE). No one
developed HAPE.
3.4. Lung function, exhaled NO and NO metabolite levels in exhaled breath
condensate
All sea level spirometry variables were normally distributed. All
subjects (2 in the treatment group smoked) had normal lung function
and there was no signiﬁcant diﬀerence seen between the placebo and
treatment groups for any sea level spirometry variable when tested (see
Table 1).
All measured breathing and salivary variables were normally dis-
tributed after log transformation. As shown in Table 2, Table 4 and
Fig. 2. Representative results of the daily diary morning routine recording resting vital signs and symptoms of Acute Mountain Sickness (AMS). No signiﬁcant diﬀerence was seen
between the low nitrate group (placebo) and the high nitrate group (intervention) in peripheral oxygen saturation (SpO2), respiratory rate, heart rate, systolic blood pressure, diastolic
blood pressure or Lake Louise Score (for AMS) on testing at sea level in London (75m), on participants' ﬁrst day at 3611m or on the ﬁrst testing day at 4559m (D1 in Fig. 1).
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Fig. 3 nitrate supplementation and hypobaric exposure both robustly
increased ENO levels, and this result remained signiﬁcant after adjusting
for multiple comparisons. Nitrate supplementation also signiﬁcantly
increased nitrite concentrations in EBC.
When modeled for days spent at altitude, dietary nitrate supple-
mentation signiﬁcantly increased ENO levels (p= 0.02), with median
values from 1.5 mPA (IQR 1.2–2.6) to 2.99mPa (IQR 1.98–4.44) at sea
level and from 3.4 mPa (IQR 1.8–4.6) to 7.4 mPA (IQR 3.9–10.4) by day
5 at altitude. In the same model, treatment with high nitrate supple-
mentation also signiﬁcantly increased sea level nitrite concentrations in
EBC (p= 0.004), with median values increasing from 1.66 μM (IQR
1.29–1.80) to 5.05 μM (IQR 1.22–9.95) at sea level, and from 1.64 μM
(IQR 1.04–2.09) to 6.26 μM (IQR 3.83–8.16) after 5 days at 4559m.
Moreover, association analyses unmasked moderate correlations be-
tween measured EBC breath nitrite and ENO levels both at sea level,
(rs= 0.29, p= 0.56 & rs= 0.54, p=0.0003 in the placebo and treat-
ment groups respectively) and at altitude (rs=−0.5, p > 0.999 &
rs= 0.18, p= 0.27 respectively). However, this analysis was limited by
low n values at sea level, particularly in the treatment group (see
Fig. 3). Changes in breath RXNO levels in response to the dietary sup-
plement followed similar trends, but these diﬀerences did not reach
statistical signiﬁcance (p=0.23). No signiﬁcant change was seen in
EBC nitrate concentrations with levels remaining very similar in both
treatment groups across the study period (p= 0.59). Median con-
centrations of nitrate in the low and high nitrate supplements were
1.84 μM (IQR 1.41–2.24) and 2.20 μM (IQR 1.29–2.9) respectively at
sea level, and 1.17 μM (IQR 0.93–1.31) and 1.20 μM (IQR 1.08–1.39)
after 5 days at altitude.
3.5. Oral nitrate reduction and NO metabolite levels in saliva
Similar to EBC, salivary NO metabolite levels at sea level and high
altitude varied considerably between individuals. Dietary nitrate sup-
plementation signiﬁcantly increased salivary levels of nitrate
(p < 0.001), nitrite (p < 0.001) and RXNO (p= 0.04) (see Table 3
and Fig. 4). Median salivary nitrate concentrations increased at sea
level from 0.79mM (IQR 0.49–0.95mM) to 5.19mM (IQR
4.07–5.91mM) upon nitrate supplementation, and after 5 days at alti-
tude from 0.64mM (IQR 0.47–1.29mM) to 4.55mM (IQR
3.44–5.98mM). Median salivary nitrite concentrations also increased
with nitrate supplementation, from 56.5 μM (IQR 17.1–147.3) to
332.8 μM (IQR 133.0–460.2) at sea level, and from 85.6 μM (IQR
37.28–155.04) to 340.9 μM (IQR 282.0–519.4) after 5 days at 4559m.
Initially, similar increases were also seen to median salivary RXNO
concentration with the intervention, with levels going from 547.9 nM
(IQR 340.6–3090.1) to 5696.4 nM (IQR 483.8–14897.4) at sea level
after dietary nitrate supplementation. However the diﬀerence between
the two randomisation groups was much smaller after 5 days at alti-
tude. The median RXNO concentration in the placebo group increased
from sea level to 1897.5 nM (IQR 462.2–4909.9) by day 5, whilst it fell
in the supplemented group to 3258.4 nM (IQR 1084.3–7211.9).
A secondary sensitivity analysis did not alter the signiﬁcance of any
Table 1
Summary spirometry data for all subjects at sea level. There is no signiﬁcant diﬀerence
between the placebo and treatment groups for any variable measured.
(% pred.) Placebo Treatment P value
FEV1 103.0 ± 3.5 97.6 ± 3.1 0.19
FVC 107.0 ± 2.7 93.0 ± 7.8 0.10
FEV/FVC 99.5 ± 2.3 98.9 ± 1.6 0.83
PEF (l/min) 114.0 ± 3.4 115.0 ± 3.3 0.83
FEV 25-75 92.2 ± 6.1 70.2 ± 13.6 0.15
Table 2
Descriptive table for Exhaled NO values at sea level (SL) and 1st (D1), 3rd (D3) and 5th (D5) testing days at 4559m, expressed as Fractional exhaled NO (FeNO, ppb), and after conversion
to partial pressure of exhaled NO (PeNO, mPa). Individual FeNO measurements were converted to PeNO measurements using the barometric pressure measured on the speciﬁc testing day
that each measurement was taken (sea level range: 101.8–102.4 kPa, altitude range: 77.3–79.5 kPa). Data are presented as median (IQR). There was a signiﬁcant increase in Exhaled NO
levels in response to dietary nitrate supplementation in a linear regression model.
FeNO (ppb) PeNO (mPa)
Untreated Placebo Treatment Untreated Placebo Treatment
SL 14.0 (11.2–22.8) 14.7 (11.5–25.1) 29.3 (21.0–42.6) 1.43 (1.1–2.7) 1.5 (1.2–2.6) 2.99 (1.98–4.44)
D1 27.7 (20.7–32.7) 36.3 (20.3–70.7) 92.0 (79.0–123.7) 2.2 (1.6–3.7) 2.8 (1.5–5.7) 7.3 (6.1–9.8)
D3 29.0 (11.7–42.6) 32.3 (15.8–53.8) 96.7 (68.3–129.0) 2.2 (0.9–4.0) 2.5 (1.2–4.4) 7.6 (4.9–11.6)
D5 22.8 (18.2–37.0) 43.3 (24.0–54.3) 95.0 (54.3–133.3) 1.8 (1.2–3.1) 3.4 (1.8–4.6) 7.4 (3.9–10.4)
Table 3
Descriptive table for sea level (SL) and 1st (D1), 3rd (D3) and 5th (D5) testing days at
4559m. Data are presented as median (IQR). All variables showed signiﬁcant increases in
response to dietary nitrate supplementation in a linear regression model except for ex-
haled breath condensate (EBC) nitrate and RxNO.
Placebo Treatment
Breath Nitrate
(μM)
SL 1.84 (1.42–2.24) 2.20 (1.29–2.90)
D1 1.07 (0.87–1.74) 1.56 (1.25–2.29)
D3 1.08 (0.89–1.26) 1.00 (0.92–1.45)
D5 1.17 (0.93–1.31) 1.20 (1.08–1.39)
Breath Nitrite
(μM)
SL 1.66 (1.29–1.80) 5.05 (1.22–9.95)
D1 1.15 (0.98–1.74) 4.87 (3.94–7.15)
D3 1.24 (0.91–2.08) 6.60 (4.06–11.35)
D5 1.64 (1.04–2.09) 6.26 (3.83–8.16)
Breath RxNO
(nM)
SL 12.29 (10.02–13.79) 16.15 (11.35–24.53)
D1 10.02 (8.61–12.74) 20.47 (14.85–41.89)
D3 8.29 (5.70–11.20) 26.18 (21.67–78.40)
D5 8.76 (4.69–12.68) 22.61 (18.89–32.81)
Saliva Nitrate (μM) SL 785.9 (487.7–954.2) 5194.3 (4066.2–5910.6)
D1 876.1 (499.1–1099.9) 3945.4 (2037.4–6314.8)
D3 874.5 (516.5–1126.0) 5478.1 (2525.5–12206.1)
D5 641.3 (474.2–1285.1) 4552.94 (3444.4–5975.4)
Saliva Nitrite (μM) SL 56.5 (17.1–147.3) 332.8 (133.0–460.2)
D1 41.7 (17.0–76.6) 170.9 (130.5–680.5)
D3 40.2 (13.5–84.4) 186.4 (117.5–496.5)
D5 85.6 (37.3–155.0) 340.9 (282.0–519.4)
Saliva RxNO (nM) SL 547.9 (340.6–3090.1) 5696.4 (483.8–14897.4)
D1 681.8 (289.2–1467.6) 4594.9 (632.2–5846.3)
D3 1260.0 (281.5–2478.8) 4126.22 (2087.3–5448.3)
D5 1897.50 (462.2–4909.9) 3258.41 (1084.3–7211.9)
Table 4
Correlation data for each log variable showing: regression coeﬃcient (β), 95% conﬁdence
interval and p value calculated from a linear regression model comparing the eﬀect of the
dietary nitrate taking into account the repeated measures at altitude.
Log variable β 95% Conf. int. P value
PeNO (mPa) 0.58 0.087–1.07 0.02
Breath nitrate (μM) 0.21 −0.56–0.98 0.59
Breath nitrite (μM) 1.24 0.41–2.1 0.004
Breath RxNO (μM) 0.42 −0.26–1.10 0.23
Saliva Nitrate (μM) 2.22 1.46–2.98 <0.001
Saliva Nitrite (μM) 2.35 1.21–3.49 <0.001
Saliva RxNO (nM) 1.40 0.062–2.73 0.04
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of these results. However, despite signiﬁcant increases in all of these
biochemical markers of NO availability, there was no identiﬁable dif-
ference between the intervention and placebo group in any resting
physiological variable or score of AMS severity (see Fig. 2).
4. Discussion
The novelty of the present study is that it was performed under ﬁeld
conditions (rather than at simulated altitude in a hypobaric chamber)
with mountaineer subjects residing at altitude over a prolonged period
of time. This experimental design allowed us to take serial measure-
ments in order to examine how dietary nitrate supplementation
(ingested in three equal doses throughout each day) aﬀects physiolo-
gical acclimatization to altitude.
4.1. Main ﬁndings – exhaled NO (ENO)
These results demonstrate that dietary nitrate supplementation with
a beetroot/fruit juice mixture at altitude successfully increases nitrate
availability; these increases are associated with markedly enhanced
levels of exhaled NO (ENO), and nitrate and nitrite levels in saliva as
well as nitrite concentrations in EBC throughout the duration of altitude
exposure. In addition, nitrate supplementation also increased the
steady-state concentrations of nitrosation products (S-nitrosothiols and
Fig. 3. Graphs showing mean exhaled NO and breath condensate values for control (low nitrate placebo) and supplement (high nitrate intervention) groups at sea level (SL) and days 1–5
(D1 - D5) at 4559m altitude. Where available, corresponding values for untreated laboratory staﬀ members is also presented. Signiﬁcant rises were seen in exhaled NO and breath
condensate nitrite in response to dietary nitrate treatment, but not breath condensate nitrate or RxNO. A: Partial pressure of exhaled NO (PeNO) over time, B: Breath condensate nitrate
concentration over time, C: Breath condensate nitrite concentration over time, D: Breath condensate nitrosation products (RxNO) concentration over time.
There were moderate correlations between Fractional exhaled NO (FeNO) and Exhaled Breath Condensate nitrite concentrations at sea level and at altitude in both the placebo (graph E)
and the treatment (graph F) groups. However, this analysis is limited by low n values at sea level, particularly in the treatment group. rS - correlation coeﬃcient of Spearman Rank test (no
adjustment for repeated measures).
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N-nitrosamines) in saliva and compensated for the drop in total nitroso
species content in EBC observed following ascent to high altitude.
Unexpectedly, despite these signiﬁcant biochemical changes there was
no measureable diﬀerence in SpO2, RR, BP, HR or AMS severity asso-
ciated with dietary nitrate supplementation, either at sea level or at
high altitude.
Reports on altitude-related changes in ENO of lowlanders and ex-
perimental animals are inconsistent. Data from one study in healthy
volunteers suggested that ENO levels decrease on acute exposure to al-
titude, possibly by as much as 33% at a simulated altitude of 5000m
[37]. This was thought to be due to the lower gas density at reduced
barometric pressures increasing the back diﬀusion and alveolar uptake
of NO [37,38]. By contrast, ENO levels increased upon acute nitrate
administration in another study [39]. Similarly, ENO increased in rats
exposed to 4 days of hypoxia, possibly as an adaptive response to the
increased oxidative stress seen with chronic hypoxic exposure [40]. Our
ﬁndings suggest equivalent responses might also be seen in humans at
altitude and over comparable timescales; ascent to 4559m over at least
3 days demonstrated similar increases in ENO levels in our cohort.
Growing evidence supports the notion that both NO and nitrate
metabolism play important roles in the physiological response to hy-
poxia, and also the beneﬁts that nitrate supplementation can confer on
individuals' physiological performance [10,41]. However, the physio-
logical role of ENO speciﬁcally in either of these situations is unclear,
and clinically the measurement of FeNO has mainly been as a point-of-
care test for airway inﬂammation in patients with asthma [42]. Its as-
sociation with the development of AMS is much less certain.
While it has been suggested that ENO may be associated with AMS,
this is not without controversy. One of those studies that led to this
conclusion was performed in a hypoxic chamber and subjects only ex-
perienced 6 h of exposure to a normobaric hypoxic stimulus [43].
Others suggested that ENO might correlate with the incidence of AMS,
but this was a much smaller study (n=8) where only baseline values
for FeNO were measured and subjects did not receive any dietary in-
tervention [44]. Another study demonstrating that ENO values dropped
signiﬁcantly on acute exposure to high altitude found no association
between ENO values and reported symptoms of AMS [7].
The two most striking diﬀerences between these studies and the
results presented here are our dietary intervention to boost nitrate
metabolism and the duration of hypoxic exposure. Our study measured
changes over ﬁve days at altitude whereas the studies of MacInnis et al.
and Brown et al. only looked at an acute exposure to hypoxia, mea-
suring changes up to six hours and three hours, respectively. A recent
study that explored a more prolonged exposure to hypobaric exposure
where teenage subjects received dietary nitrate supplementation on a
graded ascent over two weeks to 5300m in Nepal also reported no
change in AMS scores, lending further support to the unexpected
ﬁndings of the current study [45].
Conceivably, our nitrate supplement might not have induced a large
enough increase in ENO to generate a measurable physiological change
in either baseline observations (e.g. SpO2) or AMS score. We are not
aware of any speciﬁc data that would have quantiﬁed the increase in
ENO required to induce a change in either AMS, SpO2 or any other
measure reported here in native lowlanders. However, our nitrate
supplement successfully doubled median ENO values compared to con-
trol so that by day 5 the median ENO in the intervention arm was almost
three times higher than levels measured earlier in healthy Tibetan
highlanders [46]. Tibetans have less AMS than lowland trekkers even
with this accepted upper limit for ENO concentrations; therefore, those
supra-normal values in our cohort should have been suﬃcient to trigger
a physiologically meaningful response [47].
4.2. Exhaled breath condensate (EBC) results
EBC is being increasingly used to detect levels of airway in-
ﬂammation, monitor disease progression and also assess disease se-
verity in a number of respiratory conditions including adults and chil-
dren with atopic asthma [48,49]. However, despite oﬀering a relatively
cheap, quick, simple and non-invasive window into lung physiology, its
usefulness in altitude-related respiratory illnesses is less explored.
There is some evidence to suggest EBC could be useful in predicting
altitude-related illness. Results from a small study (5 subjects+ 11
controls) suggested that EBC analysis before and after 90min of nor-
mobaric hypoxic (12% oxygen) exposure might be able to distinguish
between individuals with and without a history of HAPE [50]. Mean-
while, another study demonstrated that EBC measurements conducted
Fig. 4. Graphs to values for placebo (low nitrate) and intervention (high nitrate) groups at sea level (day 0) and days 1, 3 & 5 at 4559m altitude. All values showed signiﬁcant increases in
response to treatment with dietary nitrate. A: Salivary nitrate over time, B: Salivary nitrite over time, C: Salivary RxNO over time.
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at 670m and 3000m of malondialdehyde (MDA), a marker of oxidative
stress, signiﬁcantly correlated with the AMS scores of 10 soldiers at
5000m as they ascended a 6125m peak [51]. Other oxidative stress
markers (e.g. 8-iso prostaglandin F2α) have also been shown to sig-
niﬁcantly increase in EBC measurements in small numbers of both ex-
ercising biathletes (n=10) and sedentary volunteers (n=5) over a six
week period at 2800m, further supporting our ﬁndings presented here
[52]. In a study similar to ours also making EBC measurements at
4342m from seven subjects receiving dietary L-arginine supplementa-
tion – an intervention that should increase endogenous NO production
via the classical nitric oxide synthase pathway - no improvement in
AMS scores were seen with supplementation. In fact, this study found
that the treatment group actually developed signiﬁcantly worse head-
aches [53].
Again, the biggest diﬀerence between all of these previous studies
and the results we present here is the scale of the study. To the best of
our knowledge, the Xtreme Alps expedition is currently the largest
study and 4559m is also the highest altitude at which EBC samples
have yet been collected. While no association was found between NO
metabolite related changes in EBC and AMS in the present study, future
well-powered studies are needed to determine whether or not this
technique could help predict or diagnose altitude illness using other
biomarkers.
A curious ﬁnding was that nitrite and nitrate concentrations in EBC
measured in the present study were almost identical. This is unlike any
other compartment where nitrate levels are typically exceeding nitrite
levels by at least an order of magnitude. Moreover, we found that
dietary nitrate resulted in signiﬁcant rises to levels of EBC nitrite - with
almost identical rises seen both at sea level and at altitude - but almost
no diﬀerence to EBC nitrate. This strongly suggests that both EBC ni-
trate and nitrite are under active regulatory control, even when the
exact mechanisms of sensing and regulation remain unclear. We also
noted moderate associations between levels of EBC nitrite and FeNO,
even in the low nitrate/placebo group and particularly at altitude. We
believe that, for the ﬁrst time, this provides evidence to suggest that
nitrite in airway secretions might be acting as a possible source of ENO.
Whether or not these observations are of biological signiﬁcance war-
rants further investigation.
4.3. Enterosalivary nitrate circulation
The physiological importance of the enterosalivary nitrate circula-
tion has only been realised recently whilst the conversion of L-arginine
and oxygen to NO and citrulline by NOS enzymes was established two
decades earlier [54,55]. NOS-independent nitric oxide production was
not discovered until the mid 1990s [56,57]. Unlike NOS enzymes, the
bacterial nitrate-reductase enzymes that convert nitrate to nitrite in the
oral cavity function also function in the absence of oxygen. This means
that this enterosalivary nitrate circulation becomes particularly im-
portant under hypoxic conditions when NOS activity becomes limited
[58,59], and nitrite-reducing pathways in mammalian tissues are still
inhibited by the remaining oxygen levels [13].
Dietary nitrate supplementation initially increased the levels of
salivary nitrate, nitrite and nitrosation products as expected – extra oral
nitrate availability enables more bacterial nitrate to nitrite conversion,
leading to enhanced systemic nitrite availability and formation of
downstream nitrosation products [60]. However, it is surprising that
hypoxic exposure did not signiﬁcantly alter salivary nitrate or nitrite
levels from sea level values. Moreover, we did not expect prolonged
altitude exposure to narrow the diﬀerence in salivary RXNO con-
centrations between the two groups. The cause for this ﬁnding is not
clear at present but this could be related to the duration of exposure as
the trends suggest levels might still not have reached a plateau by day
5. Equally this could suggest that chronic hypoxic conditions might
limit the maximum RXNO production rate, eﬀectively placing a ceiling
on the changes any dietary nitrate supplementation might induce.
4.4. Dietary nitrate and altitude illness
Our ﬁndings suggest that even though dietary nitrate supple-
mentation at altitude results in increased biochemical nitrate avail-
ability, this does not improve acclimatization and/or reduce the in-
cidence of AMS. Another hypobaric chamber study recently showed
similar increases in ENO after just a single dose of sodium nitrate.
However, despite ENO increasing by 24% at a simulated altitude of
4300m, there was no demonstrable beneﬁt in isometric exercise per-
formance, forearm blood ﬂow or tissue oxygenation [39]. Meanwhile
another study, which recently exposed 20 healthy volunteers to 6 h of
12% oxygen in a normobaric chamber, actually showed an increase in
AMS scores (particularly headache) with dietary nitrate, contrasting
our ﬁndings [61]. Inhaled NO has previously been shown to reduce
pulmonary arterial pressures both at sea level and at altitude, oﬀering
particular beneﬁt to HAPE-susceptible patients who tend to have high
pulmonary artery pressures [11,12]. One explanation of these ﬁndings
perhaps is that even a mild vasodilatory eﬀect on the pulmonary vas-
culature confers beneﬁts at altitude, particularly in people with natu-
rally high pulmonary artery pressures. Meanwhile any cerebrovascular
dilation in patients results in increased cerebrovascular ﬂow and wor-
sening of headache symptoms, particularly in those most susceptible to
AMS.
4.5. Strengths and limitations
The Xtreme Alps study is one of the earliest double-blinded rando-
mised placebo controlled trials of dietary nitrate supplementation at
altitude that the authors are aware of, and also one of the larger studies
to investigate the eﬀects of nitrate metabolism at altitude. Nevertheless,
absolute numbers remain rather moderate in each arm of the trial; we
also had a number of missing data points due to subjects not being able
to participate on some test days, usually due to altitude related illness.
Consequently, conﬁdence intervals remained wide in all reported
measures so we cannot completely exclude a type-2 error, although a
sensitivity analysis to correct for these missing values did not change
these outcomes.
Since the Xtreme Alps study was conducted, other studies have
emerged that also investigated how nitrate supplementation may aﬀect
performance at altitude, however most have used a simulated
(chamber) altitude environment. In accordance with our ﬁndings, AMS
incidence was shown to be similar to controls in cyclists taking dietary
nitrate supplements exposed to short sessions of 11% oxygen in a
normobaric chamber [62]. Similarly, short-term nitrate supplementa-
tion induced no signiﬁcant changes in cognitive performance in healthy
volunteers simulating hiking at altitude by walking on a treadmill in a
normobaric chamber [63]. Curiously and contrary to our ﬁndings, all of
these simulated altitude studies reported increases in SpO2 after nitrate
supplementation [62–66]. The reason for this discrepancy is not clear.
However, all of these results were in response to a very diﬀerent phy-
siological stimulus to the intervention presented here. Our subjects
were exposed to hypobaric hypoxia gradually over a number of days; in
chamber studies subjects tend to experience a much shorter duration
and more rapidly induced period of normobaric hypoxia. For example,
in one normobaric chamber study reporting an increase in cycling
performance after just one dose of nitrate, subjects were decompressed
to 15% oxygen in just 5 min [64]. Equally, the physiological response to
normobaric and hypobaric hypoxia may not be the same, as suggested
by a recent systematic review [67]. Currently Xtreme Alps remains the
largest ﬁeld study to date to explore the eﬀects of dietary nitrate by
taking serial measurements over a prolonged duration of hypobaric
hypoxic exposure at high altitude.
Another study strength was the fact that the supplement we used to
deliver nitrate (a natural beetroot/fruit juice blend) was almost iden-
tical in taste, appearance and composition to the placebo (the same
mixture except that the beetroot/fruit juice was selectively reduced in
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nitrate). Ours is the only study we are aware of that also monitored
nitrite and nitrate intake with the food.
As alluded to before, ascent occurred in two successive phases but
inclement weather conditions meant that these ascent proﬁles could not
be identical. However, statistical modeling has allowed us to control for
these diﬀerences in ascent proﬁle as much as possible, and trends be-
tween both ascent groups were similar. With each subject starting their
beetroot juice supplement (containing either high nitrate 'treatment' or
very low nitrate 'placebo') three days prior to each testing period, this
meant we were unable to record baseline values at either sea level or at
altitude. We were also unable to take a complete third 'treatment free'
control group to altitude without reducing the power of the study due
to the space available at 4559m. However, the few measurements that
were taken on the small number of treatment free laboratory team
members all closely matched those of the placebo group suggesting that
the low nitrate placebo supplement taken by this group did indeed
behave as a placebo agent.
The majority of our subjects were young, non-smoking males with
previous altitude experience, which is unsurprising given we primarily
recruited from a mailing list of medical scientists and healthcare
workers with an interest in high-altitude travel and hypoxia physiology.
This sample remains representative of lowlanders who visit high alti-
tude regions, as> 83% of patients seen at the Himalayan Rescue
Association's Everest Base Camp clinic over a ten-year period were male
with an average age less than 40 [68]. Larger studies with a broader
sample population might further strengthen this area of research in the
future.
5. Conclusions
This study suggests that dietary nitrate supplementation is tolerable
and safe at high altitude and robustly increases levels of ENO as well as
nitrate and nitrite concentrations in saliva, and nitrite concentrations in
EBC. The association between EBC nitrite and FeNO levels suggests that
exhaled NO may originate, at least in part, from nitrite in alveolar
lining ﬂuid. However, these increases in NO and related metabolites
were not associated with any measureable changes in AMS, peripheral
oxygen saturation or vital physiological parameters such as heart rate
and blood pressure after ﬁve days of hypobaric hypoxic exposure.
Future eﬀorts should be directed at investigating whether dietary ni-
trate supplementation at altitude is associated with other physiological
changes.
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